Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) has issued an announcement.
Clarity Pharmaceuticals Ltd has released its corporate governance statement for the financial year ending June 30, 2025, which adheres to the ASX Corporate Governance Council’s principles and recommendations. The statement, available on the company’s website, outlines the company’s compliance with governance standards, which is crucial for maintaining transparency and accountability to stakeholders.
The most recent analyst rating on (AU:CU6) stock is a Buy with a A$5.70 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals Ltd is a company operating in the pharmaceutical industry, focusing on radiopharmaceutical therapies and imaging. The company is involved in the development and commercialization of products that utilize radiopharmaceuticals for diagnostic and therapeutic purposes.
Average Trading Volume: 3,427,266
Technical Sentiment Signal: Sell
Current Market Cap: A$1.15B
Find detailed analytics on CU6 stock on TipRanks’ Stock Analysis page.